MICA-129 genotype, soluble MICA, and anti-MICA antibodies as biomarkers of chronic graft-versus-host disease

Blood

Volumn 114, Issue 25, 2009, Pages 5216-5224

  Boukouaci, Wahid ^a,b   Busson, Marc ^a,b   De Latour, Régis Peffault ^b   Rocha, Vanderson ^b   Suberbielle, Caroline ^a,b   Bengoufa, Djaouida ^a,b   Dulphy, Nicolas ^a,b   Haas, Philippe ^a,b   Scieux, Catherine ^b   Amroun, Habiba ^a,b   Gluckman, Eliane ^b   Krishnamoorthy, Rajagopal ^c   Toubert, Antoine ^a,b   Charron, Dominique ^a,b   Socié, Gérard ^b,d   Tamouza, Ryad ^a,b  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c HÔPITAL ROBERT DEBRÉ   (France)

^d INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; BUSULFAN; CYCLOSPORIN; MEMBRANE PROTEIN; MEMBRANE PROTEIN MICA129; METHOTREXATE; UNCLASSIFIED DRUG; ALUMINUM SILICATE; ANTIBODY; BIOLOGICAL MARKER; HLA ANTIGEN CLASS 1; MHC CLASS I RELATED CHAIN A; MHC CLASS I-RELATED CHAIN A; MICA;

ACUTE DISEASE; ADOLESCENT; ADULT; ARTICLE; BLOOD LEVEL; CHRONIC DISEASE; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENOTYPE; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA SYSTEM; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; RELAPSE; RISK ASSESSMENT; SIBLING; WHOLE BODY RADIATION; BLOOD; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY; MULTIVARIATE ANALYSIS; SOLUBILITY; TIME;

ADOLESCENT; ADULT; ALUMINUM SILICATES; ANTIBODIES; BIOLOGICAL MARKERS; CHRONIC DISEASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; MALE; MULTIVARIATE ANALYSIS; PHENOTYPE; POLYMORPHISM, GENETIC; SOLUBILITY; TIME FACTORS; YOUNG ADULT;

EID: 73949090146     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-04-217430     Document Type: Article

References (52)

1. Fraser CJ, Bhatia S, Ness K, et al. Impact of chronic graft-versus-host disease on the health status of hematopoietic cell transplantation survivors: a report from the Bone Marrow Transplant Survivor Study. Blood. 2006;108(8):2867-2873.
2. Santos GW, Hess AD, Vogelsang GB. Graft-versus-host reactions and disease. Immunol Rev. 1985;88:169-192.
3. Ferrara JLM, Antin JH. The pathophysiology of graft-versus-host disease. In: Blume KG, Forman SJ, Appelbaum SJ, Malden MA, eds. Thomas' Hematopoietic Cell Transplantation. Malden, MA: Blackwell Science; 1999:305-368.
4. Cutler C, Antin JH. Chronic graft-versus-host disease. Curr Opin Oncol. 2006;18(2):126-131.
5. Tyndall A, Dazzi F. Chronic GVHD as an autoimmune disease. Best Pract Res Clin Haematol. 2008;21(2):281-289.
6. Schultz KR, Miklos DB, Fowler D, et al. Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease, III: Biomarker Working Group Report. Biol Blood Marrow Transplant. 2006;12(2):126-137.
7. Shimada M, Onizuka M, Machida S, et al. Association of autoimmune disease-related gene polymorphisms with chronic graft-versus-host disease. Br J Haematol. 2007;139(3):458-463.
8. Bogunia-Kubik K, Wysoczanska B, Lange A. Non-HLA gene polymorphisms and the outcome of allogeneic hematopoietic stem cell transplantation. Curr Stem Cell Res Ther. 2006;1(2):239-253.
9. Fujii H, Cuvelier G, She K, et al. Biomarkers in newly diagnosed pediatric-extensive chronic graft-versus-host disease: a report from the Children's Oncology Group. Blood. 2008;111(6): 3276-3285.
10. She K, Gilman AL, Aslanian S, et al. Altered Toll-like receptor 9 responses in circulating B cells at the onset of extensive chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2007; 13(4):386-397.
11. Imamura M, Hashino S, Kobayashi H, et al. Serum cytokine levels in bone marrow transplantation: synergistic interaction of interleukin-6, interferon-gamma, and tumor necrosis factor-alpha in graft-versus-host disease. Bone Marrow Transplant. 1994;13(6):745-751.
12. Bahram S. MIC genes: from genetics to biology. Adv Immunol. 2000;76:1-60.
13. Bahram S, Inoko H, Shiina T, Radosavljevic M. MIC and other NKG2D ligands: from none to too many. Curr Opin Immunol. 2005;17(5):505-509.
14. Eagle RA, Trowsdale J. Promiscuity and the single receptor: NKG2D. Nat Rev Immunol. 2007; 7(9):737-744.
15. Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature. 2002;419(6908): 734-738.
16. Salih HR, Rammensee HG, Steinle A. Cutting edge: down-regulation of MICA on human tumors by proteolytic shedding. J Immunol. 2002;169(8): 4098-4102.
17. Groh V, Bruhl A, El-Gabalawy H, Nelson JL, Spies T. Stimulation of T cell autoreactivity by anomalous expression of NKG2D and its MIC ligands in rheumatoid arthritis. Proc Natl Acad Sci U S A. 2003;100(16):9452-9457.
18. Suárez-Alvarez B, López-Vázquez A, Díaz-Molina B, et al. The predictive value of soluble major histocompatibility complex class I chainrelated molecule A (MICA) levels on heart allograft rejection. Transplantation. 2006;82(3):354-361.
19. Schrambach S, Ardizzone M, Leymarie V, Sibilia J, Bahram S. In vivo expression pattern of MICA and MICB and its relevance to auto-immunity and cancer. PLoS ONE. 2007;2(6):e518; 1-10.
20. European Bioinformatics Institute. IMGT/HLA (ImMunoGeneTics/ histocompatibility complex) Sequence Database. http://www.ebi.ac.uk/imgt/hla/. Accessed August 16, 2009.
21. Stastny P, Zou Y, Fan Y, Qin Z, Lavingia B. The emerging issue of MICA antibodies: antibodies to MICA and other antigens of endothelial cells. Contrib Nephrol. 2009;162:99-106.
22. Steinle A, Li P, Morris DL, et al. Interactions of human NKG2D with its ligands MICA, MICB, and homologs of the mouse RAE-1 protein family. Immunogenetics. 2001;53(4):279-287.
23. Amroun H, Djoudi H, Busson M, et al. Early-onset ankylosing spondylitis is associated with a functional MICA polymorphism. Hum Immunol. 2005; 66(10):1057-1061.
24. Douik H, Chaaben AB, Romdhane NA, et al. Association of MICA-129 polymorphism with nasopharyngeal cancer risk in a Tunisian population. Hum Immunol. 2009;70(1):45-48.
25. Rocha V, Franco RF, Porcher R, et al. Host defense and inflammatory gene polymorphisms are associated with outcomes after HLA-identical sibling bone marrow transplantation. Blood. 2002; 100(12):3908-3918.
26. Fine JP, Gray RJ. A proportional hazards model for the sub distribution of a competing risk. J Am Stat Assoc. 1999;94:496.
27. Cox DR. Regression models and life tables (with discussion). J R Stat Soc Series B Stat Methodol. 1972;34:187-220.
28. Fraser CJ, Scott Baker K. The management and outcome of chronic graft-versus-host disease. Br J Haematol. 2007;138(2):131-145.
29. Pavletic SZ, Carter SL, Kernan NA, et al. Influence of T-cell depletion on chronic graft-versus-host disease: results of a multicenter randomized trial in unrelated marrow donor transplantation. Blood. 2005;106(9):3308-3313.
30. Schultz KR, Paquet J, Bader S, HayGlass KT. Requirement for B cells in T cell priming to minor histocompatibility antigens and development of graft-versus-host disease. Bone Marrow Transplant. 1995;16(2):289-295.
31. Zhang C, Todorov I, Zhang Z, et al. Donor CD4 T and B cells in transplants induce chronic graft versus- host disease with autoimmune manifestations. Blood. 2006;107(7):2993-3001.
32. Imanguli MM, Swaim WD, League SC, Gress RE, Pavletic SZ, Hakim FT. Increased T-bet+ cytotoxic effectors and type I interferon-mediated processes in chronic graft versus host disease of the oral mucosa. Blood. 2009;113(15):3620-3630.
33. Kim DH, Sohn SK, Lee NY, et al. Transplantation with higher dose of natural killer cells associated with better outcomes in terms of non-relapse mortality and infectious events after allogeneic peripheral blood stem cell transplantation from HLA-matched sibling donors. Eur J Haematol. 2005; 75(4):299-308.
34. Larghero J, Rocha V, Porcher R, et al. Association of bone marrow natural killer cell dose with neutrophil recovery and chronic graft-versus-host disease after HLA identical sibling bone marrow transplants. Br J Haematol. 2007;138(1):101-109
35. Hüe S, Mention JJ, Monteiro RC, et al. A direct role for NKG2D/MICA interaction in villous atrophy during celiac disease. Immunity. 2004;21(3): 367-377.
36. Ogasawara K, Hamerman JA, Ehrlich LR, et al. NKG2D blockade prevents autoimmune diabetes in NOD mice. Immunity. 2004;20(6):757-767.
37. Caillat-Zucman S. How NKG2D ligands trigger autoimmunity? Hum Immunol. 2006;67(3):204-207.
38. Dulphy N, Haas P, Busson M, et al. An unusual CD56(bright) CD16(low) NK cell subset dominates the early posttransplant period following HLA-matched hematopoietic stem cell transplantation. J Immunol. 2008;181(3):2227-2237.
39. Tivol E, Komorowski R, Drobyski WR. Emergent autoimmunity in graft-versus-host disease. Blood. 2005;105(12):4885-4891.
40. Asai O, Longo DL, Tian ZG, et al. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation. J Clin Invest. 1998;101(9):1835-1842.
41. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295(5562):2097-2100.
42. Lü M, Xia B, Ge L, et al. Role of major histocompatibility complex class I-related molecules A*A5.1 allele in ulcerative colitis in Chinese patients. Immunology. 2008;128:e230-e236.
43. Gao X, Single RM, Karacki P, Marti D, O'Brien SJ, Carrington M. Diversity of MICA and linkage disequilibrium with HLA-B in two North American populations. Hum Immunol. 2006;67(3):152-158.
44. Holdenrieder S, Stieber P, Peterfi A, Nagel D, Steinle A, Salih HR. Soluble MICA in malignant diseases. Int J Cancer. 2006;118(3):684-687.
45. Salih HR, Antropius H, Gieseke F, et al. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood. 2003;102(4):1389-1396.
46. Kaiser BK, Yim D, Chow IT, et al. Disulphide-isomerase-enabled shedding of tumour-associated NKG2D ligands. Nature. 2007; 447(7143):482-486.
47. Waldhauer I, Goehlsdorf D, Gieseke F, et al. Tumor-associated MICA is shed by ADAM proteases. Cancer Res. 2008;68(15):6368-6376.
48. Arreygue-Garcia NA, Daneri-Navarro A, del Toro-Arreola A, et al. Augmented serum level of major histocompatibility complex class I-related chain A (MICA) protein and reduced NKG2D expression on NK and T cells in patients with cervical cancer and precursor lesions. BMC Cancer. 2008;8:16.
49. Peraldi MN, Berrou J, Dulphy N, et al. Oxidative stress mediates a reduced expression of the activating receptor NKG2D in NK cells from end-stage renal disease patients. J Immunol. 2009; 182(3):1696-1705.
50. Holdenrieder S, Eichhorn P, Beuers U, et al. Soluble NKG2D ligands in hepatic autoimmune diseases and in benign diseases involved in marker metabolism. Anticancer Res. 2007; 27(4A):2041-2045.
51. Jinushi M, Vanneman M, Munshi NC, et al. MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma. Proc Natl Acad Sci U S A. 2008;105(4):1285-1290.
52. Jinushi M, Hodi FS, Dranoff G. Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity. Proc Natl Acad Sci U S A. 2006;103(24):9190-9915